View ValuationThis company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsByotrol 将来の成長Future 基準チェック /06現在、 Byotrolの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Chemicals 収益成長43.1%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報お知らせ • Nov 14Byotrol plc Provides Sales Guidance for the Full Year Ending March 31, 2024Byotrol plc provided sales guidance for the full year ending March 31, 2024. For the year, the company expects product sales of approximately £3.9 million, which shows modest growth on £3.7 million in the previous year on a like-for-like basis (excluding discontinued items). Including discontinued items, prior year product sales were £4.3 million.お知らせ • Jul 11Byotrol plc Provides Earnings Guidance for the Full Year Ended March 31, 2022Byotrol plc provided earnings guidance for the full year ended March 31, 2022. For the period, the company expected Sales of £6.3 million, comprising £5.2 million from product sales and £1.1 million from IP sales and royalties.お知らせ • Apr 24Byotrol plc Provides Earnings Guidance for the Full Year Ended March 31, 2021Byotrol plc provided earnings guidance for the full year ended March 31, 2021. For the period, the company expected turnover to be in excess of £11 million compared to £6.1 million a year ago.すべての更新を表示Recent updatesお知らせ • Mar 28Byotrol plc, Annual General Meeting, Apr 22, 2024Byotrol plc, Annual General Meeting, Apr 22, 2024, at 10:00 Coordinated Universal Time. Location: Riverbank House, 2 Swan Lane, - London United KingdomReported Earnings • Dec 09First half 2024 earnings released: UK£0.002 loss per share (vs UK£0.001 loss in 1H 2023)First half 2024 results: UK£0.002 loss per share (further deteriorated from UK£0.001 loss in 1H 2023). Revenue: UK£2.02m (down 9.4% from 1H 2023). Net loss: UK£742.0k (loss widened 28% from 1H 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 25 percentage points per year, which is a significant difference in performance.New Risk • Nov 14New major risk - Revenue and earnings growthEarnings have declined by 14% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (153% average daily change). Earnings have declined by 14% per year over the past 5 years. Market cap is less than US$10m (€3.39m market cap, or US$3.68m). Minor Risks Less than 1 year of cash runway based on current free cash flow (-UK£1.5m). Currently unprofitable and not forecast to become profitable next year (UK£800k net loss next year).お知らせ • Nov 14Byotrol plc Provides Sales Guidance for the Full Year Ending March 31, 2024Byotrol plc provided sales guidance for the full year ending March 31, 2024. For the year, the company expects product sales of approximately £3.9 million, which shows modest growth on £3.7 million in the previous year on a like-for-like basis (excluding discontinued items). Including discontinued items, prior year product sales were £4.3 million.お知らせ • Sep 27Byotrol plc Announces Chief Executive Officer ChangesByotrol plc announced that Vivan Pinto, CEO of the Company, has stepped down as CEO and left the Company to pursue other opportunities. David Traynor formerly Byotrol CEO 2013 - 2022 has kindly agreed to act as interim CEO until a suitable replacement for Vivan is appointed.お知らせ • Sep 08Byotrol plc Announces the Appointment of Ashley Head to the Board as an Independent Non-Executive Director, with Effect from 13 September 2023Byotrol plc announced the appointment of Ashley Head to the Board as an independent Non-Executive Director, with effect from AGM on 13 September 2023. Ashley began his career with Chase Manhattan Bank, where he rose through the ranks of technology and online banking. He then joined MasterCard, where he became responsible for the African region of the group. After recognising the opportunities within eCommerce Ashley founded Proc Cyber, growing the business to a valuation of over £60 million in three years and then merging with Datacash in 2006 where he assumed the role of Chairman. Under Ashley's leadership, Datacash grew to a market leading position with MasterCard purchasing the company in 2010. Ashley continues to lead a vibrant portfolio career and currently serves as Chairman of The AI Corporation, MySense Group and Champagne Piaff in addition to other director positions. He is also a trustee for the National Emergency Trust, Epsom College and Stonegate Foundation.お知らせ • Aug 30Byotrol plc Announces Launch of CHEMGENE MEDLAB into Human HealthcareByotrol plc announced the launch into human healthcare of its next-generation surface disinfection chemistry, branded CHEMGENE MEDLAB. The CHEMGENE brand, previously marketed by Medimark Scientific Ltd. and acquired by Byotrol in 2018, enjoys a long-standing reputation as a trusted choice for disinfecting surfaces and equipment across emergency services, laboratories, and human health organisations. This new formulation is designed for market-leading, broad-spectrum efficacy, low toxicity and regulatory approval across the UK and EU under the increasingly stringent biocidal regulations. CHEMGENE MEDLAB Multi-Surface Disinfectants are very effective against bacteria, yeasts, fungi, and viruses, with specifically tailored efficacy against: The ESKAPE group of bacteria, targeted in healthcare environments for their multi-drug resistance, and virulence. Critical viruses, including Norovirus, Adenovirus, and the Vaccinia virus-the accepted surrogate for enveloped viruses such as Coronavirus, HIV, Hepatitis B & C, and Herpes Simplex virus. Emerging fungus Candida auris, known for its global health threat due to multi-drug resistance and ease of transmission within healthcare settings. CHEMGENE MEDLAB Multi-Surface Disinfectants are supported by rigorous microbiological testing to the latest European efficacy test methodologies, including stringent medical standards that simulate high soil conditions akin to the presence of blood and other organic fluids during disinfection.New Risk • Aug 24New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: €8.74m (US$9.46m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (37% average weekly change). Market cap is less than US$10m (€8.74m market cap, or US$9.46m). Minor Risk Less than 1 year of cash runway based on current free cash flow (-UK£1.5m).Reported Earnings • Jul 31Full year 2023 earnings released: UK£0.26 loss per share (vs UK£0.003 loss in FY 2022)Full year 2023 results: UK£0.26 loss per share (further deteriorated from UK£0.003 loss in FY 2022). Revenue: UK£4.59m (down 27% from FY 2022). Net loss: UK£1.69m (loss widened 26% from FY 2022). Revenue is expected to decline by 20% p.a. on average during the next 3 years, while revenues in the Chemicals industry in Germany are expected to grow by 2.2%. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 143 percentage points per year, which is a significant difference in performance.New Risk • Jun 14New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended September 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-UK£1.9m free cash flow). Share price has been highly volatile over the past 3 months (43% average weekly change). Minor Risks Latest financial reports are more than 6 months old (reported September 2022 fiscal period end). Currently unprofitable and not forecast to become profitable next year (UK£471k net loss next year). Market cap is less than US$100m (€10.1m market cap, or US$10.9m).New Risk • Jun 12New minor risk - ProfitabilityThe company is currently unprofitable and not forecast to become profitable over the next year. Trailing 12-month net loss: UK£1.8m Forecast net loss in 1 year: UK£471k This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-UK£1.9m free cash flow). Share price has been highly volatile over the past 3 months (43% average weekly change). Minor Risks Currently unprofitable and not forecast to become profitable next year (UK£471k net loss next year). Market cap is less than US$100m (€10.1m market cap, or US$10.8m).お知らせ • May 25Byotrol plc Announces EPA Approval for Long-Lasting Performance Against Virucidal ClaimsByotrol Plc announced that the US Environmental Protection Agency ("EPA") has formally approved long-lasting virucidal claims for its proprietary 24-hour germ-kill surface sanitizer Byotrol 24 (EPA Reg. Number 83614-1). This approval was received by the Company after close of business, on 22 May 2023. The Directors believe that this is the first product to receive such EPA approval and means that Byotrol24 and its sub brands will now be able to offer unique and highly relevant claims and performance characteristics to US consumers and businesses. This includes being able to claim efficacy against certain current and emerging viral pathogens including influenza, coronavirus and norovirus (via the commonly accepted surrogate feline calicivirus). The Company continues to advance alliances and commercial opportunities in the US, including with a previously announced, well-known sub-licensee in the US institutional market, which is continuing to prepare a market launch with the new product claims at the forefront of its marketing strategy.Reported Earnings • Dec 13First half 2023 earnings released: UK£0.13 loss per share (vs UK£0 in 1H 2022)First half 2023 results: UK£0.13 loss per share (further deteriorated from UK£0 in 1H 2022). Revenue: UK£2.23m (down 30% from 1H 2022). Net loss: UK£579.0k (loss widened 391% from 1H 2022). Revenue is forecast to grow 27% p.a. on average during the next 3 years, while revenues in the Chemicals industry in Germany are expected to remain flat. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 117 percentage points per year, which is a significant difference in performance.お知らせ • Nov 22Byotrol plc Announces Management ChangesByotrol plc announced the following long-planned board changes. John Langlands, Non-Executive Chairman since February 2017, has notified the Board of his retirement from business and to step-down as Chairman and as a Director of Byotrol. John originally only intended to serve as Chairman of Byotrol for five years, but has remained slightly longer to guide the Company through this year's AGM. John will initially remain as a Non Executive Director to aid the leadership transition, but will then retire as a Director on 31 January 2023, having completed 6 years of service. David Traynor, Chief Executive Officer since October 2013 is moving to Executive Chairman, with immediate effect. In addition to his responsibilities as Chairman, David will now focus on securing and developing intellectual property agreements and commercial alliances for the Company. Vivan Pinto, currently Byotrol's Chief Growth Officer, and formerly VP and Area MD at Johnson and Johnson Consumer Health, is being promoted to Chief Executive Officer and joins the Board as an Executive Director with immediate effect. He will now assume formal responsibility for the day-to-day sales and operations of the Company, working closely with Chris Sedwell, Executive Director and Chief Financial Officer.Board Change • Nov 17No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. CFO & Director Chris Sedwell was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.Reported Earnings • Oct 20Full year 2022 earnings released: UK£0.003 loss per share (vs UK£0.002 profit in FY 2021)Full year 2022 results: UK£0.003 loss per share (down from UK£0.002 profit in FY 2021). Revenue: UK£6.33m (down 44% from FY 2021). Net loss: UK£1.35m (down 238% from profit in FY 2021). Over the last 3 years on average, earnings per share has fallen by 55% per year but the company’s share price has increased by 16% per year, which means it is well ahead of earnings.Reported Earnings • Sep 01Full year 2022 earnings released: UK£0.003 loss per share (vs UK£0.002 profit in FY 2021)Full year 2022 results: UK£0.003 loss per share (down from UK£0.002 profit in FY 2021). Revenue: UK£6.33m (down 44% from FY 2021). Net loss: UK£1.35m (down 238% from profit in FY 2021). Over the last 3 years on average, earnings per share has fallen by 44% per year but the company’s share price has increased by 21% per year, which means it is well ahead of earnings.お知らせ • Sep 01Byotrol plc, Annual General Meeting, Sep 22, 2022Byotrol plc, Annual General Meeting, Sep 22, 2022, at 10:00 Coordinated Universal Time.お知らせ • Jul 29Byotrol plc announced that it has received £1 million in fundingByotrol plc announced a private placement of convertible loan notes for gross proceeds of £1,000,000 on July 28, 2022. The transaction included participation from new investors C Sedwell, Chief Financial Officer for £50,000, S Gogarty, Non-Executive Director for £100,000 and returning investors D Traynor, Chief Executive Officer for £50,000, V Pinto, Chief Growth Officer for £100,000, and T Francis, Non-Executive Director for £200,000. The loan notes have a term of five years, are senior in ranking, unsecured and convertible at investors' option into ordinary shares in the capital of the company at a price of £0.0325 (3.25 pence) per ordinary share, representing a 30% premium to the mid-price of the company's share price at close of business on 26 July 2022. The loan notes carry a coupon of 9% per annum, payable quarterly in arrears.お知らせ • Jul 11Byotrol plc Provides Earnings Guidance for the Full Year Ended March 31, 2022Byotrol plc provided earnings guidance for the full year ended March 31, 2022. For the period, the company expected Sales of £6.3 million, comprising £5.2 million from product sales and £1.1 million from IP sales and royalties.Board Change • Apr 27No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. CFO & Director Chris Sedwell was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.Reported Earnings • Aug 21Full year 2021 earnings released: EPS UK£0.002 (vs UK£0.001 in FY 2020)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2021 results: Revenue: UK£11.2m (up 85% from FY 2020). Net income: UK£979.0k (up 193% from FY 2020). Profit margin: 8.7% (up from 5.5% in FY 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 109% per year but the company’s share price has only increased by 18% per year, which means it is significantly lagging earnings growth.お知らせ • Apr 24Byotrol plc Provides Earnings Guidance for the Full Year Ended March 31, 2021Byotrol plc provided earnings guidance for the full year ended March 31, 2021. For the period, the company expected turnover to be in excess of £11 million compared to £6.1 million a year ago.お知らせ • Feb 27Byotrol plc Announces That It Has Developed and Externally Validated A New Test for Determining Whether Cleaning and Sanitising ProductsByotrol plc announced that it has developed and externally validated a new test for determining whether cleaning and sanitising products have long-lasting efficacy against viruses in real-life use. This new test determines whether sanitising and cleaning products offer any long-lasting protection against COVID-19. Byotrol is now standing behind product efficacy claims supporting infection control products that offer 24-hour protection against viruses and bacteria in real-life conditions, where surfaces are frequently touched. The Company believes that this new test could help minimise the spread of the virus when used in conjunction with the cleaning and sanitising of shops, schools and offices when they reopen. The company has developed the new test in response to an increasing number of products claiming long-lasting efficacy against coronavirus, based on laboratory conditions which ignore the constant abrasion of surfaces in real-life environments (and which would then make many products ineffective). The company developed the industry standard test for long-lasting efficacy in real-life against bacteria and yeast in 2014 with the help of independent industry experts. The test, named PAS 2424:2014, was approved by the British Standards Institute (BSI) and is the only British standard to prove the efficacy of a disinfectant product over 24 hours. The PAS 2424:2014 test is currently being reviewed by the CEN Committee for approval as a new European EN test standard. This new test for viruses simulates 'real-life' conditions by creating frequent abrasions on surfaces after products have been applied, to replicate frequent touching of surfaces throughout the day. The surfaces are then tested to see whether the product is still present and killing viruses. The test is limited to 24 hours, to ensure that the result is attributed to the efficacy of the product, not the length of time the virus has been left to dry out on a surface, which could result in a false positive. The company plans to gain approval from the BSI again, to make this new test the British standard for proving the long-lasting efficacy of disinfectants against viruses. The application of this test could help businesses and consumers select products which are proven to be effective in a variety of public spaces where surfaces are frequently touched, genuinely promoting public health.Reported Earnings • Dec 10First half 2021 earnings released: EPS UK£0.002The company reported a strong first half result with improved earnings, revenues and profit margins. First half 2021 results: Revenue: UK£6.67m (up 207% from 1H 2020). Net income: UK£1.01m (up UK£1.64m from 1H 2020). Profit margin: 15% (up from net loss in 1H 2020). The move to profitability was driven by higher revenue.お知らせ • Nov 14Byotrol plc Announces Retirement of Till Medinger from the BoardByotrol plc now confirm the formal retirement of Dr. Till Medinger from the Board.Reported Earnings • Oct 14Full year earnings released - EPS €0.00077Over the last 12 months the company has reported total profits of UK£334.0k, down 5.6% from the prior year. Total revenue was UK£6.07m over the last 12 months, up 7.1% from the prior year. Profit margins were 5.5%, which is in line with last year.Analyst Estimate Surprise Post Earnings • Oct 14Annual earnings released: Revenue beats expectationsAnnual revenue exceeded analyst estimates by 1.2% at UK£6.07m. Revenue is forecast to grow 89% over the next year, while the growth in Chemicals industry in Germany is expected to stay flat. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Byotrol は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測DB:B7Y - アナリストの将来予測と過去の財務データ ( )GBP Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数3/31/20245-10019/30/20234-200N/A6/30/20234-2-1-1N/A3/31/20235-2-1-1N/A12/31/20225-2-2-1N/A9/30/20225-2-2-2N/A6/30/20226-2-1-1N/A3/31/20226-1-10N/A12/31/20217-100N/A9/30/20218000N/A6/30/20219000N/A3/31/202111101N/A9/30/202010201N/A6/30/20208100N/A3/31/202061-10N/A12/31/201961-1-1N/A9/30/201971-1-1N/A6/30/20196100N/A3/31/20196000N/A12/31/20184-100N/A9/30/20182-2-1-1N/A6/30/20182-2-1-1N/A3/31/20182-2-2-1N/A12/31/20172-1-1-1N/A9/30/20173000N/A6/30/201730N/A0N/A3/31/201730N/A0N/A12/31/201630N/A0N/A9/30/20162-1N/A-1N/A6/30/20162-1N/A0N/A3/31/20163-1N/A0N/A12/31/20153-1N/A0N/A9/30/20153-1N/A0N/A6/30/20153-1N/A-1N/A3/31/20153-1N/A-1N/A12/31/20143-1N/A-1N/A9/30/20143-1N/A-1N/A6/30/20143-1N/A-1N/A3/31/20143-1N/A-1N/A12/31/20133-1N/A-1N/A9/30/20133-2N/A-1N/A6/30/20133-2N/A-1N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: B7Yの予測収益成長が 貯蓄率 ( 0.7% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: B7Yの収益がGerman市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: B7Yの収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: B7Yの収益がGerman市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: B7Yの収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: B7Yの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YMaterials 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2024/06/05 17:10終値2024/04/29 00:00収益2023/09/30年間収益2023/03/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Byotrol plc 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。4 アナリスト機関David BuxtonCavendishAndrew Murray DarleyCavendishStephen McGarryCavendish1 その他のアナリストを表示
お知らせ • Nov 14Byotrol plc Provides Sales Guidance for the Full Year Ending March 31, 2024Byotrol plc provided sales guidance for the full year ending March 31, 2024. For the year, the company expects product sales of approximately £3.9 million, which shows modest growth on £3.7 million in the previous year on a like-for-like basis (excluding discontinued items). Including discontinued items, prior year product sales were £4.3 million.
お知らせ • Jul 11Byotrol plc Provides Earnings Guidance for the Full Year Ended March 31, 2022Byotrol plc provided earnings guidance for the full year ended March 31, 2022. For the period, the company expected Sales of £6.3 million, comprising £5.2 million from product sales and £1.1 million from IP sales and royalties.
お知らせ • Apr 24Byotrol plc Provides Earnings Guidance for the Full Year Ended March 31, 2021Byotrol plc provided earnings guidance for the full year ended March 31, 2021. For the period, the company expected turnover to be in excess of £11 million compared to £6.1 million a year ago.
お知らせ • Mar 28Byotrol plc, Annual General Meeting, Apr 22, 2024Byotrol plc, Annual General Meeting, Apr 22, 2024, at 10:00 Coordinated Universal Time. Location: Riverbank House, 2 Swan Lane, - London United Kingdom
Reported Earnings • Dec 09First half 2024 earnings released: UK£0.002 loss per share (vs UK£0.001 loss in 1H 2023)First half 2024 results: UK£0.002 loss per share (further deteriorated from UK£0.001 loss in 1H 2023). Revenue: UK£2.02m (down 9.4% from 1H 2023). Net loss: UK£742.0k (loss widened 28% from 1H 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 25 percentage points per year, which is a significant difference in performance.
New Risk • Nov 14New major risk - Revenue and earnings growthEarnings have declined by 14% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (153% average daily change). Earnings have declined by 14% per year over the past 5 years. Market cap is less than US$10m (€3.39m market cap, or US$3.68m). Minor Risks Less than 1 year of cash runway based on current free cash flow (-UK£1.5m). Currently unprofitable and not forecast to become profitable next year (UK£800k net loss next year).
お知らせ • Nov 14Byotrol plc Provides Sales Guidance for the Full Year Ending March 31, 2024Byotrol plc provided sales guidance for the full year ending March 31, 2024. For the year, the company expects product sales of approximately £3.9 million, which shows modest growth on £3.7 million in the previous year on a like-for-like basis (excluding discontinued items). Including discontinued items, prior year product sales were £4.3 million.
お知らせ • Sep 27Byotrol plc Announces Chief Executive Officer ChangesByotrol plc announced that Vivan Pinto, CEO of the Company, has stepped down as CEO and left the Company to pursue other opportunities. David Traynor formerly Byotrol CEO 2013 - 2022 has kindly agreed to act as interim CEO until a suitable replacement for Vivan is appointed.
お知らせ • Sep 08Byotrol plc Announces the Appointment of Ashley Head to the Board as an Independent Non-Executive Director, with Effect from 13 September 2023Byotrol plc announced the appointment of Ashley Head to the Board as an independent Non-Executive Director, with effect from AGM on 13 September 2023. Ashley began his career with Chase Manhattan Bank, where he rose through the ranks of technology and online banking. He then joined MasterCard, where he became responsible for the African region of the group. After recognising the opportunities within eCommerce Ashley founded Proc Cyber, growing the business to a valuation of over £60 million in three years and then merging with Datacash in 2006 where he assumed the role of Chairman. Under Ashley's leadership, Datacash grew to a market leading position with MasterCard purchasing the company in 2010. Ashley continues to lead a vibrant portfolio career and currently serves as Chairman of The AI Corporation, MySense Group and Champagne Piaff in addition to other director positions. He is also a trustee for the National Emergency Trust, Epsom College and Stonegate Foundation.
お知らせ • Aug 30Byotrol plc Announces Launch of CHEMGENE MEDLAB into Human HealthcareByotrol plc announced the launch into human healthcare of its next-generation surface disinfection chemistry, branded CHEMGENE MEDLAB. The CHEMGENE brand, previously marketed by Medimark Scientific Ltd. and acquired by Byotrol in 2018, enjoys a long-standing reputation as a trusted choice for disinfecting surfaces and equipment across emergency services, laboratories, and human health organisations. This new formulation is designed for market-leading, broad-spectrum efficacy, low toxicity and regulatory approval across the UK and EU under the increasingly stringent biocidal regulations. CHEMGENE MEDLAB Multi-Surface Disinfectants are very effective against bacteria, yeasts, fungi, and viruses, with specifically tailored efficacy against: The ESKAPE group of bacteria, targeted in healthcare environments for their multi-drug resistance, and virulence. Critical viruses, including Norovirus, Adenovirus, and the Vaccinia virus-the accepted surrogate for enveloped viruses such as Coronavirus, HIV, Hepatitis B & C, and Herpes Simplex virus. Emerging fungus Candida auris, known for its global health threat due to multi-drug resistance and ease of transmission within healthcare settings. CHEMGENE MEDLAB Multi-Surface Disinfectants are supported by rigorous microbiological testing to the latest European efficacy test methodologies, including stringent medical standards that simulate high soil conditions akin to the presence of blood and other organic fluids during disinfection.
New Risk • Aug 24New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: €8.74m (US$9.46m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (37% average weekly change). Market cap is less than US$10m (€8.74m market cap, or US$9.46m). Minor Risk Less than 1 year of cash runway based on current free cash flow (-UK£1.5m).
Reported Earnings • Jul 31Full year 2023 earnings released: UK£0.26 loss per share (vs UK£0.003 loss in FY 2022)Full year 2023 results: UK£0.26 loss per share (further deteriorated from UK£0.003 loss in FY 2022). Revenue: UK£4.59m (down 27% from FY 2022). Net loss: UK£1.69m (loss widened 26% from FY 2022). Revenue is expected to decline by 20% p.a. on average during the next 3 years, while revenues in the Chemicals industry in Germany are expected to grow by 2.2%. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 143 percentage points per year, which is a significant difference in performance.
New Risk • Jun 14New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended September 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-UK£1.9m free cash flow). Share price has been highly volatile over the past 3 months (43% average weekly change). Minor Risks Latest financial reports are more than 6 months old (reported September 2022 fiscal period end). Currently unprofitable and not forecast to become profitable next year (UK£471k net loss next year). Market cap is less than US$100m (€10.1m market cap, or US$10.9m).
New Risk • Jun 12New minor risk - ProfitabilityThe company is currently unprofitable and not forecast to become profitable over the next year. Trailing 12-month net loss: UK£1.8m Forecast net loss in 1 year: UK£471k This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-UK£1.9m free cash flow). Share price has been highly volatile over the past 3 months (43% average weekly change). Minor Risks Currently unprofitable and not forecast to become profitable next year (UK£471k net loss next year). Market cap is less than US$100m (€10.1m market cap, or US$10.8m).
お知らせ • May 25Byotrol plc Announces EPA Approval for Long-Lasting Performance Against Virucidal ClaimsByotrol Plc announced that the US Environmental Protection Agency ("EPA") has formally approved long-lasting virucidal claims for its proprietary 24-hour germ-kill surface sanitizer Byotrol 24 (EPA Reg. Number 83614-1). This approval was received by the Company after close of business, on 22 May 2023. The Directors believe that this is the first product to receive such EPA approval and means that Byotrol24 and its sub brands will now be able to offer unique and highly relevant claims and performance characteristics to US consumers and businesses. This includes being able to claim efficacy against certain current and emerging viral pathogens including influenza, coronavirus and norovirus (via the commonly accepted surrogate feline calicivirus). The Company continues to advance alliances and commercial opportunities in the US, including with a previously announced, well-known sub-licensee in the US institutional market, which is continuing to prepare a market launch with the new product claims at the forefront of its marketing strategy.
Reported Earnings • Dec 13First half 2023 earnings released: UK£0.13 loss per share (vs UK£0 in 1H 2022)First half 2023 results: UK£0.13 loss per share (further deteriorated from UK£0 in 1H 2022). Revenue: UK£2.23m (down 30% from 1H 2022). Net loss: UK£579.0k (loss widened 391% from 1H 2022). Revenue is forecast to grow 27% p.a. on average during the next 3 years, while revenues in the Chemicals industry in Germany are expected to remain flat. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 117 percentage points per year, which is a significant difference in performance.
お知らせ • Nov 22Byotrol plc Announces Management ChangesByotrol plc announced the following long-planned board changes. John Langlands, Non-Executive Chairman since February 2017, has notified the Board of his retirement from business and to step-down as Chairman and as a Director of Byotrol. John originally only intended to serve as Chairman of Byotrol for five years, but has remained slightly longer to guide the Company through this year's AGM. John will initially remain as a Non Executive Director to aid the leadership transition, but will then retire as a Director on 31 January 2023, having completed 6 years of service. David Traynor, Chief Executive Officer since October 2013 is moving to Executive Chairman, with immediate effect. In addition to his responsibilities as Chairman, David will now focus on securing and developing intellectual property agreements and commercial alliances for the Company. Vivan Pinto, currently Byotrol's Chief Growth Officer, and formerly VP and Area MD at Johnson and Johnson Consumer Health, is being promoted to Chief Executive Officer and joins the Board as an Executive Director with immediate effect. He will now assume formal responsibility for the day-to-day sales and operations of the Company, working closely with Chris Sedwell, Executive Director and Chief Financial Officer.
Board Change • Nov 17No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. CFO & Director Chris Sedwell was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
Reported Earnings • Oct 20Full year 2022 earnings released: UK£0.003 loss per share (vs UK£0.002 profit in FY 2021)Full year 2022 results: UK£0.003 loss per share (down from UK£0.002 profit in FY 2021). Revenue: UK£6.33m (down 44% from FY 2021). Net loss: UK£1.35m (down 238% from profit in FY 2021). Over the last 3 years on average, earnings per share has fallen by 55% per year but the company’s share price has increased by 16% per year, which means it is well ahead of earnings.
Reported Earnings • Sep 01Full year 2022 earnings released: UK£0.003 loss per share (vs UK£0.002 profit in FY 2021)Full year 2022 results: UK£0.003 loss per share (down from UK£0.002 profit in FY 2021). Revenue: UK£6.33m (down 44% from FY 2021). Net loss: UK£1.35m (down 238% from profit in FY 2021). Over the last 3 years on average, earnings per share has fallen by 44% per year but the company’s share price has increased by 21% per year, which means it is well ahead of earnings.
お知らせ • Sep 01Byotrol plc, Annual General Meeting, Sep 22, 2022Byotrol plc, Annual General Meeting, Sep 22, 2022, at 10:00 Coordinated Universal Time.
お知らせ • Jul 29Byotrol plc announced that it has received £1 million in fundingByotrol plc announced a private placement of convertible loan notes for gross proceeds of £1,000,000 on July 28, 2022. The transaction included participation from new investors C Sedwell, Chief Financial Officer for £50,000, S Gogarty, Non-Executive Director for £100,000 and returning investors D Traynor, Chief Executive Officer for £50,000, V Pinto, Chief Growth Officer for £100,000, and T Francis, Non-Executive Director for £200,000. The loan notes have a term of five years, are senior in ranking, unsecured and convertible at investors' option into ordinary shares in the capital of the company at a price of £0.0325 (3.25 pence) per ordinary share, representing a 30% premium to the mid-price of the company's share price at close of business on 26 July 2022. The loan notes carry a coupon of 9% per annum, payable quarterly in arrears.
お知らせ • Jul 11Byotrol plc Provides Earnings Guidance for the Full Year Ended March 31, 2022Byotrol plc provided earnings guidance for the full year ended March 31, 2022. For the period, the company expected Sales of £6.3 million, comprising £5.2 million from product sales and £1.1 million from IP sales and royalties.
Board Change • Apr 27No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. CFO & Director Chris Sedwell was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
Reported Earnings • Aug 21Full year 2021 earnings released: EPS UK£0.002 (vs UK£0.001 in FY 2020)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2021 results: Revenue: UK£11.2m (up 85% from FY 2020). Net income: UK£979.0k (up 193% from FY 2020). Profit margin: 8.7% (up from 5.5% in FY 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 109% per year but the company’s share price has only increased by 18% per year, which means it is significantly lagging earnings growth.
お知らせ • Apr 24Byotrol plc Provides Earnings Guidance for the Full Year Ended March 31, 2021Byotrol plc provided earnings guidance for the full year ended March 31, 2021. For the period, the company expected turnover to be in excess of £11 million compared to £6.1 million a year ago.
お知らせ • Feb 27Byotrol plc Announces That It Has Developed and Externally Validated A New Test for Determining Whether Cleaning and Sanitising ProductsByotrol plc announced that it has developed and externally validated a new test for determining whether cleaning and sanitising products have long-lasting efficacy against viruses in real-life use. This new test determines whether sanitising and cleaning products offer any long-lasting protection against COVID-19. Byotrol is now standing behind product efficacy claims supporting infection control products that offer 24-hour protection against viruses and bacteria in real-life conditions, where surfaces are frequently touched. The Company believes that this new test could help minimise the spread of the virus when used in conjunction with the cleaning and sanitising of shops, schools and offices when they reopen. The company has developed the new test in response to an increasing number of products claiming long-lasting efficacy against coronavirus, based on laboratory conditions which ignore the constant abrasion of surfaces in real-life environments (and which would then make many products ineffective). The company developed the industry standard test for long-lasting efficacy in real-life against bacteria and yeast in 2014 with the help of independent industry experts. The test, named PAS 2424:2014, was approved by the British Standards Institute (BSI) and is the only British standard to prove the efficacy of a disinfectant product over 24 hours. The PAS 2424:2014 test is currently being reviewed by the CEN Committee for approval as a new European EN test standard. This new test for viruses simulates 'real-life' conditions by creating frequent abrasions on surfaces after products have been applied, to replicate frequent touching of surfaces throughout the day. The surfaces are then tested to see whether the product is still present and killing viruses. The test is limited to 24 hours, to ensure that the result is attributed to the efficacy of the product, not the length of time the virus has been left to dry out on a surface, which could result in a false positive. The company plans to gain approval from the BSI again, to make this new test the British standard for proving the long-lasting efficacy of disinfectants against viruses. The application of this test could help businesses and consumers select products which are proven to be effective in a variety of public spaces where surfaces are frequently touched, genuinely promoting public health.
Reported Earnings • Dec 10First half 2021 earnings released: EPS UK£0.002The company reported a strong first half result with improved earnings, revenues and profit margins. First half 2021 results: Revenue: UK£6.67m (up 207% from 1H 2020). Net income: UK£1.01m (up UK£1.64m from 1H 2020). Profit margin: 15% (up from net loss in 1H 2020). The move to profitability was driven by higher revenue.
お知らせ • Nov 14Byotrol plc Announces Retirement of Till Medinger from the BoardByotrol plc now confirm the formal retirement of Dr. Till Medinger from the Board.
Reported Earnings • Oct 14Full year earnings released - EPS €0.00077Over the last 12 months the company has reported total profits of UK£334.0k, down 5.6% from the prior year. Total revenue was UK£6.07m over the last 12 months, up 7.1% from the prior year. Profit margins were 5.5%, which is in line with last year.
Analyst Estimate Surprise Post Earnings • Oct 14Annual earnings released: Revenue beats expectationsAnnual revenue exceeded analyst estimates by 1.2% at UK£6.07m. Revenue is forecast to grow 89% over the next year, while the growth in Chemicals industry in Germany is expected to stay flat.